Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cost of Revenue: 2021-2024

Historic Cost of Revenue for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $60.9 million.

  • Kiniksa Pharmaceuticals International's Cost of Revenue rose 0.74% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.6 million, marking a year-over-year increase of 41.88%. This contributed to the annual value of $60.9 million for FY2024, which is 82.33% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Cost of Revenue stood at $60.9 million for FY2024, which was up 82.33% from $33.4 million recorded in FY2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Cost of Revenue peaked at $60.9 million during FY2024, and registered a low of $9.1 million during FY2021.
  • Moreover, its 3-year median value for Cost of Revenue was $33.4 million (2023), whereas its average is $39.1 million.
  • Data for Kiniksa Pharmaceuticals International's Cost of Revenue shows a peak YoY surged of 151.59% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Kiniksa Pharmaceuticals International's Cost of Revenue stood at $9.1 million in 2021, then soared by 151.59% to $22.9 million in 2022, then surged by 45.91% to $33.4 million in 2023, then skyrocketed by 82.33% to $60.9 million in 2024.